Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO News

19/10/2017 09:38

Consun Pharma considering spin-off of Yulin Pharmaceutical

[ET Net News Agency, 19 October 2017] Consun Pharmaceutical (01681) said it is
considering a possible spin-off and listing of Guangxi Yulin Pharmaceutical Group Co.,
Ltd. and its subsidiaries on a stock exchange in the People's Republic of China.
Yulin Pharmaceutical is an indirect non-wholly-owned subsidiary of Consun Pharmaceutical
and is principally engaged in the business of research and development, production and
sales of Chinese medicines and natural medicines.
At this stage, Yulin Pharmaceutical has not submitted any listing application to the
China Securities Regulatory Commission, the relevant stock exchange in the PRC, the Hong
Kong Stock Exchange or other relevant regulatory authorities. (HL)

Back to IPO News

A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.